80% of preliminary molecules tested exhibit submicromolar activity and acceptable ADME properties
Simulations Plus Sets Date for Second Quarter Fiscal Year 2021 Earnings Release and Conference Call
Conference call to be on Monday, April 12, 2021, at 4:15 p.m. ET
Simulations Plus Forms Scientific Advisory Board for RENAsym Consortium
RENAsym SAB to Provide Insights and Guidance for Development of Kidney Injury Software
Simulations Plus Hosts the Inaugural 2021 MIDD+ Scientific Conference with over 50 Model-Informed Drug Development Sessions
Speakers from Academia, Large Pharma Collaborations and Regulatory Agencies shared their real-world impact using modeling & simulation technology
Simulations Plus and the University of Pittsburgh Drug Discovery Institute Receive SBIR Grant Funding for Large Molecule Safety Collaboration
Computational Modeling, Human Liver Microphysiology Systems (MPS) and the MPS-Database Platforms to be Integrated for Safety Testing
Simulations Plus to Participate in BTIG Virtual MedTech, Digital Health, Life Science and Diagnostic Tools Conference
Simulations Plus to Participate in BTIG Virtual MedTech, Digital Health, Life Science and Diagnostic Tools Conference
Simulations Plus Releases GastroPlus® Version 9.8.1
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemical, and...
Simulations Plus Enters Agreement with Distributor in China
Extends reach of MonolixSuite™ to China’s growing pharmacology market
Simulations Plus Expands Marketing and Sales Operations in South America Through Partnership with the Institute of Pharmaceutical Sciences
New distribution channel will accelerate adoption of software and services in emerging markets
Simulations Plus Awards Infrastructure Improvement Grant to Makerere University Department of Pharmacology and Therapeutics
Facilitates Access to KIWI, a Pharmacometrics Modeling and Simulation Platform
Simulations Plus Enters New Funded Collaboration to Improve Lung Exposure Models for Pulmonary Infection Treatments
Integrated machine learning and PBPK/PD methods will support discovery and development activities
Simulations Plus Reports Record First Quarter FY2021 Financial Results
First quarter revenue of $10.7 million, reflecting 14% year-over-year growth
Board of Directors announces quarterly dividend of $0.06 per share
Simulations Plus Enters New Funded Collaboration to Enhance Top-Rated GastroPlus® ACAT™ Model for Oral Absorption of Peptides
New modeling approaches will accelerate the evaluation of innovative formulation strategies
Simulations Plus Sets Date for First Quarter Fiscal Year 2021 Earnings Release and Conference Call
Conference call to be on Monday, January 11, 2021, at 4:15 p.m. ET
Simulations Plus Publishes its Inaugural Environmental, Social and Governance (ESG) Report
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemicals...
DILIsym Services Presents Important DILIsym and NAFLDsym Software Applications at the Virtual AASLD Liver Meeting
2020 Virtual Liver Meeting Posters Showcase Customer Applications
Simulations Plus Names Industry Veteran Will Frederick as Chief Financial Officer
Brings 25 years of Financial Leadership, Significant Public Company Experience, and M&A Expertise to Company
Simulations Plus Reports Fourth Quarter FY2020 Financial Results
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemicals, and consumer goods industries, today reported financial results for its 2020 fiscal year (FY20) and fourth quarter (4QFY20) ended August 31, 2020.
DILIsym Plays Critical Role in Submission to State of California for Common Analgesic Carcinogenicity Risk
Comments Submitted to California’s OEHHA Featured DILIsym Simulations